FMX101 clinical trials
Also written FMX101.
How each study uses FMX101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2016 (6)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 6 |
| 2017 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Vyne Therapeutics Inc. (8) · Cutia Therapeutics (Shanghai) Co., Ltd (1)
Studies
Open first, then newest update. How each study uses FMX101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne VulgarisCompletedPhase 3Cutia Therapeutics (Shanghai) Co., LtdNCT04960930Written as FMX101
- A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe AcneCompletedPhase 3Vyne Therapeutics Inc.NCT02815280Written as FMX-101, 4% minocycline foam
- A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe AcneCompletedPhase 3Vyne Therapeutics Inc.NCT02815267Written as FMX-101, 4% minocycline foam
- A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne VulgarisCompletedPhase 3Vyne Therapeutics Inc.NCT03271021Written as FMX101
- A Pharmacokinetic Study of Minocycline in Male and Female VolunteersCompletedPhase 1Vyne Therapeutics Inc.NCT02250859Written as FMX101, Minocycline 4% foam
- Dermal Phototoxicity StudyCompletedPhase 1Vyne Therapeutics Inc.NCT04070742Written as FMX101
- Dermal Cumulative Irritant Patch StudyCompletedPhase 1Vyne Therapeutics Inc.NCT04064125Written as FMX-101
- Dermal Photo Allergic Skin ReactionCompletedPhase 1Vyne Therapeutics Inc.NCT04070755Written as FMX-101
- A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test DesignCompletedPhase 1Vyne Therapeutics Inc.NCT04052711Written as FMX-101